National Cancer Institute CARCINOGENESIS Technical Report Series

No. 17 1977

BIOASSAY OF PHOTODIELDRIN FOR POSSIBLE CARCINOGENICITY

CAS No. 13366-73-9

NCI-CG-TR-17

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service National Institutes of Health



BIOASSAY OF

PHOTODIELDRIN

FOR POSSIBLE CARCINOGENICITY

Carcinogen Bioassay and Program Resources Branch Carcinogenesis Program Division of Cancer Cause and Prevention National Cancer Institute National Institutes of Health Bethesda, Maryland 20014

DHEW Publication No. (NIH) 77-817

·

BIOASSAY OF PHOTODIELDRIN FOR POSSIBLE CARCINOGENICITY

Carcinogenesis Program Division of Cancer Cause and Prevention National Cancer Institute National Institutes of Health

<u>CONTRIBUTORS</u>: This report presents the results of the bioassay of photodieldrin for possible carcinogenicity, conducted for the Carcinogen Bioassay and Program Resources Branch, Carcinogenesis Program, Division of Cancer Cause and Prevention, National Cancer Institute (NCI), Bethesda, Maryland. The bioassay was conducted by Gulf South Research Institute, New Iberia, Louisiana, initially under direct contract to NCI and currently under a subcontract to Tracor Jitco, Inc., prime contractor for the NCI carcinogenesis bioassay program.

The experimental design was determined by Drs. J. H. Weisburger^{1,2} and R. R. Bates^{1,3}; the doses were selected by Drs. T. E. Shellenberger^{4,5}, J. H. Weisburger, and R. R. Bates. Animal treatment and observation were supervised by Drs. T. E. Shellenberger and H. P. Burchfield⁴, with the technical assistance of Ms. D. H. Monceaux⁴ and Mr. D. Broussard⁴. Histopathology was performed by Drs. E. Bernal⁴ and B. Buratto⁴ at Gulf South Research Institute, and the diagnoses included in this report represent the interpretation of these pathologists.

Animal pathology tables and survival tables were compiled at EG&G Mason Research Institute⁶. Statistical analyses were performed by Dr. J. R. Joiner⁷, using methods selected for the bioassay program by Dr. J. J. Gart⁸. Chemicals used in this bioassay were analyzed under the direction of Dr. H. P. Burchfield, and the analytical results were reviewed by Dr. S. S. Olin⁷.

This report was prepared at Tracor Jitco under the direction of NCI. Those responsible for the report at Tracor Jitco were Dr. Marshall Steinberg, Director of the Bioassay Program;

Drs. J. F. Robens⁷ and C. H. Williams⁷, toxicologists; Dr. R. L. Schueler⁷, pathologist; Ms. Y. E. Presley⁷, technical writer; and Dr. E. W. Gunberg⁷, technical editor, assisted by Ms. P. J. Graboske⁷.

The statistical analysis was reviewed by a member or members of the Mathematical Statistics and Applied Mathematics Section of NCI (Dr. John J. Gart, Mr. Jun-mo Nam, Dr. Hugh M. Pettigrew, and Dr. Robert E. Tarone served as reviewers on an alternating basis).

The following other scientists at the National Cancer Institute were responsible for evaluating the bioassay experiment, interpreting the results, and reporting the findings:

> Dr. Kenneth C. Chu Dr. Cipriano Cueto, Jr. Dr. J. Fielding Douglas Dr. Dawn G. Goodman Dr. Richard A. Griesemer Dr. Thomas W. Orme Mr. Harry A. Milman Dr. Robert A. Squire⁹ Dr. Jerrold M. Ward

¹Carcinogenesis Program, Divison of Cancer Cause and Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

²Now with the Naylor Dana Institute for Disease Prevention, American Health Foundation, Hammond House Road, Valhalla, New York.

³Now with the Office of the Commissioner, Food and Drug Administration, Rockville, Maryland.

⁴Gulf South Research Institute, Atchafalaya Basin Laboratories, P. O. Box 1177, New Iberia, Louisiana.

⁵Now with the National Center for Toxicological Research, Jefferson, Arkansas. ⁶EG&G Mason Research Institute, 1530 East Jefferson Street, Rockville, Maryland.

⁷Tracor Jitco, Inc., 1776 East Jefferson Street, Rockville, Maryland.

⁸Mathematical Statistics and Applied Mathematics Section, Biometry Branch, Field Studies and Statistics, Division of Cancer Cause and Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

⁹Now with the Division of Comparative Medicine, Johns Hopkins University, School of Medicine, Traylor Building, Baltimore, Maryland. .

SUMMARY

A bioassay of dieldrin-free photodieldrin (synthesized by Gulf South Research Institute) for possible carcinogenicity was conducted by administering the test material in feed to Osborne-Mendel rats and B6C3F1 mice.

Groups of 50 rats of each sex were initially administered photodieldrin at one of two doses, either 5 or 10 ppm. Because of neurotoxic signs, doses in the females were reduced after 30 Total periods of treatment for low- and high-dose males weeks. and low-dose females were 80 weeks, followed by periods of 31 or 32 weeks of additional observation; the total period of treatment for the high-dose females was 59 weeks, followed by a period of additional observation of 53 weeks. The time-weighted average doses for the females were 3.4 or 7.5 ppm. Matched controls consisted of 10 untreated rats of each sex; pooled controls, used controls for statistical evaluation, consisted of the matched combined with 65 untreated male and 65 untreated female rats from similarly performed bioassays of six other test chemicals. A11 surviving rats were killed at 111-112 weeks.

Groups of 50 mice of each sex were administered photodieldrin at one of two doses, either 0.32 or 0.64 ppm, for 80 weeks, then observed for an additional 13 weeks. Matched controls consisted of groups of 10 untreated mice of each sex at each dose; pooled controls, used for statistical evaluation, consisted of the matched controls combined with 60 untreated male and 60 untreated female mice from similarly performed bioassays of six other test chemicals. All surviving mice were killed at 93 weeks.

Mean body weights attained by low- and high-dose male and female rats and mice were essentially unaffected by photodieldrin. Convulsions and hyperactivity were noted in treated male and female rats and in male mice. Mortality rates of either sex or either species were not affected by treatment. In rats, benign tumors (adenoma and fibroadenoma) of the mammary gland in females showed a dose-related trend (P = 0.039) compared with matched, but not pooled, controls (8/72 pooled controls, 0/9 matched controls, 5/50 low-dose, 10/49 high-dose). Adenocarcinoma of the mammary gland occurred in two additional low-dose females. The incidences of these tumors in either of the treated groups were not significantly higher than those in the control groups using either matched or pooled controls. Three papillary and follicular-cell adenomas and one papillary adenocarcinoma of the thyroid occurred in the low-dose females, giving a statistically significant increase over the pooled controls (P = 0.022), but these thyroid tumors did not occur in the high-dose The dose-related trend was not statistically signifianimals. cant using either pooled or matched controls, and the incidence in the low-dose group is not greater than that in the historical In male rats, the incidence of hemangiomas showed a controls. statistically significant dose-related trend (P = 0.021) using pooled controls, but the direct comparison of the three hemangiomas in the high-dose group with the pooled-control group was not statistically significant. Furthermore, three hemangiomas is a small number, and the tumors occurred in more than one anatomic site (two in the spleen, one in subcutaneous The occurrence of these tumors cannot clearly be tissue). associated with treatment.

In mice, there were no tumors that were statistically significant in treated groups of either sex.

It is concluded that under the conditions of this bioassay, photodieldrin was not carcinogenic for Osborne-Mendel rats or B6C3F1 mice.

TABLE OF CONTENTS

I.	Intro	duction	1
II.	Mater	ials and Methods	3
	А. В. С. Д. Е. F. G. H.	Chemical Dietary Preparation. Animals. Animal Maintenance. Subchronic Studies. Designs of Chronic Studies. Clinical and Pathologic Examinations. Data Recording and Statistical Analyses.	3 4 5 7 8 11 12
III.	. Resu	lts - Rats	19
	A. B. C. D.	Body Weights and Clinical Signs (Rats) Survival (Rats) Pathology (Rats) Statistical Analyses of Results (Rats)	19 19 21 23
IV.	Resu	lts - Mice	27
	A. B. C. D.	Body Weights and Clinical Signs (Mice) Survival (Mice) Pathology (Mice) Statistical Analyses of Results (Mice)	27 27 30 31
۷.	Disc	ussion	33
VI.	Bibl	iography	37
		APPENDIXES	
Арр	endix	A Summary of the Incidence of Neoplasms in Rats Fed Photodieldrin in the Diet	39
Т	able A	l Summary of the Incidence of Neoplasms in Male Rats Fed Photodieldrin in the Diet	41
Т	able A	2 Summary of the Incidence of Neoplasms in Female Rats Fed Photodieldrin in the Diet	45

Appendix B	Summary of the Incidence of Neoplasms in Mice Fed Photodieldrin in the Diet	49
Table Bl	Summary of the Incidence of Neoplasms in Male Mice Fed Photodieldrin in the Diet	51
Table B2	Summary of the Incidence of Neoplasms in Female Mice Fed Photodieldrin in the Diet	54
Appendix C	Summary of the Incidence of Nonneoplastic Lesions in Rats Fed Photodieldrin in the Diet	57
Table Cl	Summary of the Incidence of Nonneoplastic Lesions in Male Rats Fed Photodieldrin in the Diet	59
Table C2	Summary of the Incidence of Nonneoplastic Lesions in Female Rats Fed Photodieldrin in the Diet	63
Appendix D	Summary of the Incidence of Nonneoplastic Lesions in the Mice Fed Photodieldrin in the Diet	67
Table Dl	Summary of the Incidence of Nonneoplastic Lesions in the Male Mice Fed Photodieldrin in the Diet	69
Table D2	Summary of the Incidence of Nonneoplastic Lesions in Female Mice Fed Photodieldrin in the Diet	72
Appendix E	Analyses of the Incidence of Primary Tumors in Rats Fed Photodieldrin in the Diet	75
Table El	Analyses of the Incidence of Primary Tumors in Male Rats Fed Photodieldrin in the Diet	77
Table E2	Analyses of the Incidence of Primary Tumors in Female Rats Fed Photodieldrin in the Diet	82

.

Appendix F	Analyses of the Incidence of Primary Tumors in Mice Fed Photodieldrin in the Diet	87
Table Fl	Analyses of the Incidence of Primary Tumors in Male Mice Fed Photodieldrin in the Diet	89
Table F2	Analyses of the Incidence of Primary Tumors in Female Mice Fed Photodieldrin in the Diet	92
Appendix G	Analysis of Formulated Diets for Concentrations of Photodieldrin	95

.

Page

TABLES

Table l	Design of Photodieldrin Chronic Feeding Studies in Rats	9
Table 2	Design of Photodieldrin Chronic Feeding Studies in Mice	10

FIGURES

Figure l	Growth Curves for Rats Fed Photodieldrin in the Diet	20
Figure 2	Survival Curves for Rats Fed Photodieldrin in the Diet	22
Figure 3	Growth Curves for Mice Fed Photodieldrin in the Diet	28
Figure 4	Survival Curves for Mice Fed Photodieldrin in the Diet	29

xi

I. INTRODUCTION

Photodieldrin (CAS 13366-73-9; NCI C00599) is a photochemical conversion product of dieldrin with the systematic name 1, 1, 2, 3, 3a, 7a-hexachloro-exo-5,6-epoxydecahydro-2,4,7-metheno-lH-cyclopenta[a] pentalene. It is a half-cage structure derived from the bridging of C-12 to C-9 in dieldrin with transfer of a C-12 hydrogen to C-10. Photoconversion is carried out in sunlight and by certain microorganisms that have been isolated from soil, water, rat intestine, and the rumen stomach contents of cows (Matsumura et al., 1970). The photochemical rearrangement and oxidation of aldrin and photoaldrin also will yield photodieldrin (Brooks, Under certain conditions, photodieldrin is persistent in 1975). the environment as a terminal residue of dieldrin (Matsumura, 1973; Brooks, 1975). Photodieldrin is more toxic than dieldrin to rats and mice but less toxic to dogs, chickens, and pheasants (Brooks, 1975).

Although it has never been produced commercially, photodieldrin was selected for testing in 1969 because it was a photochemical conversion product of dieldrin. At that time dieldrin was used extensively as a pesticide.

II. MATERIALS AND METHODS

A. Chemical

Gulf South Research Institute synthesized two batches of photodieldrin for use in the chronic study. The method, based on that described by Chau et al. (1971) for the preparation of photoheptachlor ketone, involved irradiating a solution of dieldrin in acetone at 2537 Å under nitrogen.

The first batch was synthesized from dieldrin obtained from Shell Chemical Company, Modesto, California, which had been purified by recrystallization. Photodieldrin was obtained in a 59% yield after three recrystallizations of the irradiated product from ethanol.

The second batch was prepared from technical-grade dieldrin, giving photodieldrin in a 48% yield after seven recrystallizations.

All analytical tests performed showed that both batches were identical to a reference sample of photodieldrin. Parameters compared included melting point (191.5-193°C), ir spectrum, thin-layer chromatograms, and gas-liquid chromatograms on two dissimilar columns. Neither batch contained any detectable residual dieldrin. The absence of dieldrin was also confirmed in

analyses of these batches by Shell Development Company, Modesto, California. No attempt was made to identify or quantitate impurities.

The chemical was stored in amber glass containers at $0^{\circ}C$.

B. Dietary Preparation

All diets were formulated using Wayne[®] Lab Blox (Allied Mills, Inc., Chicago, Ill.) to which was added the required amount of photodieldrin for each dietary concentration. The test chemical was first dissolved in a small amount of acetone (Mallinckrodt Inc., St. Louis, Mo.), which was then added to the feed. Corn oil (Louana[®], Opelousas Refinery Co., Opelousas, La.) was also added to the feed, primarily as a dust suppressant, and the diets were mixed mechanically to assure homogeneity of the mixtures and evaporation of the acetone. Final diets, including those for the control groups of animals, contained corn oil equal to 2% of the final weight of feed. The diets were stored at approximately 17° C until used, but no longer than 1 week.

The stability of photodieldrin in feed was tested by determining the concentration of the chemical in formulated diets at intervals over a 7-day period. Diets containing 0.32, 0.64, 2.5, 5.0, or 10.0 ppm photodieldrin showed no change in concentration on standing at ambient temperature for this period.

As a quality control test on the accuracy of preparation of the diets, the concentration of photodieldrin was determined in different batches of formulated diets during the chronic study. The results are summarized in Appendix G. At each dietary concentration, the mean of the analytical concentrations for the checked samples was within 1.6% of the theoretical concentration, and the coefficient of variation was never more than 5.8%. Thus, the evidence indicates that the formulated diets were prepared accurately.

C. Animals

Rats and mice of both sexes, obtained through contracts of the Division of Cancer Treatment, National Cancer Institute, were used in these bioassays. The rats were of the Osborne-Mendel strain obtained from Battelle Memorial Institute, Columbus, Ohio, and the mice were B6C3F1 hybrids obtained from Charles River Breeding Laboratories, Inc., Wilmington, Massachusetts. On arrival at the laboratory, all animals were quarantined for an acclimation period (rats for 9 days, mice for 14 days) and were then assigned to control and treated groups.

D. Animal Maintenance

All animals were housed in temperature- and humidity-controlled rooms. The temperature range was 22-24 °C, and the relative

humidity was maintained at 40-70%. The air in each room was changed 10-12 times per hour. Fluorescent lighting provided illumination 10 hours per day. Food and water were supplied <u>ad</u> <u>libitum</u>.

The rats were housed individually in hanging galvanized steel mesh cages, and the mice were housed in plastic cages with filter bonnets, five per cage for females, and two or three per cage for males. Initially, rats were transferred once per week to clean cages; later in the study, cages were changed every 2 weeks. Mice were transferred once per week to clean cages covered with filter bonnets; bedding used for the mice was Absorb-Dri[®] (Lab Products, Inc., Garfield, N. J.). For rats, absorbent sheets under the cages were changed three times per week. Feeder jars and water bottles were changed and sterilized three times per week.

Cages for control and treated mice were placed on separate racks in the same room. Animal racks for both species were rotated laterally once per week; at the same time each cage was changed to a different position in the row within the same column. Rats receiving photodieldrin, along with their matched controls, were housed in a room by themselves. Mice receiving photodieldrin were maintained in a room housing mice administered aldrin (CAS

309-00-2) or captan (CAS 133-06-2), together with their respective matched controls.

E. Subchronic Studies

Subchronic feeding studies were conducted with rats and mice to estimate the maximum tolerated doses of photodieldrin, on the basis of which low and high concentrations (hereinafter referred to as "low doses" and "high doses") were determined for administration in the chronic studies. In the subchronic studies, photodieldrin was added to the animal feed in twofold increasing concentrations, ranging from 2.5 to 80.0 ppm for rats and 0.01 to 0.32 ppm for mice. Control and treated groups each consisted of five male and five female animals. The chemical was provided in feed to treated groups for 6 weeks, followed by a 2-week period of observation. Because there were no deaths in the mice, and because the gains in body weights of the treated groups of mice were similar to those of the control group during the entire study, a second study was performed in mice, with doses ranging from 0.04 to 2.56 ppm. In the second study, the chemical was provided in feed to treated groups for 6 weeks, followed by a 3-week period of observation.

At 40 and 80 ppm, all rats died during week 2. In males receiving 20 ppm or less there was no evidence of significant

behavioral changes or other clinical signs except heavy shedding of hair. Throughout the 8-week study, all treated females lost weight. At 20 ppm the females appeared hyperactive. During week 6 tachypnea was noted in one female and hyperactivity in another female receiving 10 ppm photodieldrin. The low and high doses for rats were set at 5 and 10 ppm for the chronic studies.

There were no marked adverse effects in mice receiving 1.28 ppm. At 2.56 ppm all mice died by week 6. The low and high doses for mice were set at 0.32 and 0.64 ppm for the chronic studies.

F. Designs of Chronic Studies

The designs of the chronic studies are shown in tables 1 and 2.

Since the numbers of animals in the matched-control groups were small, pooled-control groups also were used for statistical comparisons. Matched controls from the current studies on photodieldrin were combined with matched controls from studies performed on malathion (CAS 121-75-5), tetrachlorvinphos (CAS 961-11-5), toxaphene (CAS 8001-35-2), lindane (CAS 58-89-9), endrin (CAS 72-20-8), and captan. The pooled controls for statistical tests using rats consisted of 75 males and 75 females; using mice, 80 males and 80 females. The studies on chemicals other than photodieldrin were also conducted at Gulf South Research Institute and overlapped the photodieldrin study

Initial		Timo	on Study	Time-Weighted
	dieldrin in Diet (ppm)	Treated	on Study Untreated ^b (weeks)	Average Dose ^C
		<u></u>	<u></u>	- Malaine
10	0		111 112	
10	0		111-112	
50	5 0	80	31-32	5
50	10 0	80	32	10
10	0		111	
50	5 2.5 ^d 0	30 50	32	3.4
50	10 5 ^d 0	30 29	53	7.5
	50 10 50	Animals ^a (ppm) 10 0 50 $5 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ $	Animals ^a (ppm)(weeks)10050 5 8050108010050 5 50 5 50 5 50 5 50 5 50 5 50 10 50 5 50 10 50 10 50 10 50 2.5^{d} 50 2.9^{d}	Animals ^a (ppm) (weeks) (weeks) 10 0 111-112 50 5 80 31-32 50 10 80 32 10 0 111 50 $5_{2.5d}$ 30_{20} 10 0 111 50 $5_{2.5d}$ $50_{2.5d}$ 30_{22} 50 10_{5d} 30_{29} 32_{20}

Table 1. Design of Photodieldrin Chronic Feeding Studies in Rats

^aAll animals were 35 days of age when placed on study.

^bWhen diets containing photodieldrin were discontinued, high-dose females and their matched controls were fed control diets without corn oil for 8.5 weeks, then control diets (2% corn oil added) for an additional 44 weeks. All males, low-dose females, and their matched controls were fed control diets until termination of the study.

^cTime-weighted average dose = $\sum (\text{dose in ppm x no. of weeks at that dose})$ $\sum (\text{no. of weeks receiving each dose})$

^dBecause of neurotoxic signs, doses in female rats were reduced after 30 weeks.

Sex and	Initial	Photodieldrin	Time or	
	No. of	in Diet	Treated	Untreated ^b
Group	<u>Animals</u> a	(ppm)	(weeks)	(weeks)
Male				
Low-Dose Matched-Control	10	0		93
High-Dose Matched-Control	c 10	0		93
Low-Dose	50	0.32 0	80	13
High-Dose ^C	50	0.64 0	80	13
Female				
Low-Dose Matched-Control	10	0		93
High-Dose Matched-Control	c 10	0		93
Low-Dose	50	0.32 0	80	13
High-Dose ^c	50	0.64 0	80	13 13

Table 2. Design of Photodieldrin Chronic Feeding Studies in Mice

^aAll animals were 35 days of age when placed on study.

^bWhen diets containing photodieldrin were discontinued, mice received control diets until termination of the study.

^CDue to high mortality caused by an error in the preparation of the feed mix, studies for high-dose male and high-dose female mice were terminated; the studies were then restarted using 10 additional matched-control mice.

by at least 1 year. The matched-control groups for the different test chemicals were of the same strain and from the same supplier, and they were examined by the same pathologists.

G. Clinical and Pathologic Examinations

All animals were observed twice daily for signs of toxicity, weighed at regular intervals, and palpated for masses at each weighing. Animals that were moribund at the time of clinical examination were killed and necropsied.

The pathologic evaluation consisted of gross and microscopic examination of major tissues, major organs, and all gross lesions from animals found from killed animals and dead. The following tissues were examined microscopically: skin, lungs and bronchi, trachea, bone and bone marrow, spleen, lymph nodes, heart, salivary gland, liver, gallbladder (mice), pancreas, stomach, small intestine, large intestine, kidney, urinary bladder, pituitary, adrenal, thyroid, parathyroid, mammary gland, prostate or uterus, testis or ovary, and brain. Occasionally additional tissues were also examined microscopically. The different tissues were preserved in 10% buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Special staining techniques were utilized when indicated for more definitive diagnosis.

A few tissues from some animals were not examined, particularly from those animals that died early. Also, some animals were missing, cannibalized, or judged to be in such an advanced state of autolysis as to preclude histopathologic evaluation. Thus, the number of animals from which particular organs or tissues were examined microscopically varies, and does not necessarily represent the number of animals that were placed on study in each group.

H. Data Recording and Statistical Analyses

Pertinent data on this experiment have been recorded in an automatic data processing system, the Carcinogenesis Bioassay Data System (Linhart et al., 1974). The data elements include descriptive information on the chemicals, animals, experimental design, clinical observations, survival, body weight, and individual pathologic results, as recommended by the International Union Against Cancer (Berenblum, 1969). Data tables were generated for verification of data transcription and for statistical review.

These data were analyzed using the statistical techniques described in this section. Those analyses of the experimental results that bear on the possibility of carcinogenicity are discussed in the statistical narrative sections.

Probabilities of survival were estimated by the product-limit

procedure of Kaplan and Meier (1958) and are presented in this report in the form of graphs. Animals were statistically censored as of the time that they died of other than natural causes or were found to be missing; animals dying from natural causes were not statistically censored. Statistical analyses for a possible dose-related effect on survival used the method of Cox (1972) for testing two groups for equality and Tarone's (1975) extensions of Cox's methods for testing for a dose-related trend. One-tailed P values have been reported for all tests except the departure from linearity test, which is only reported when its two-tailed P value is less than 0.05.

The incidence of neoplastic or nonneoplastic lesions has been given as the ratio of the number of animals bearing such lesions at a specific anatomic site (numerator) to the number of animals in which that site is examined (denominator). In most instances, the denominators included only those animals for which that site was examined histologically. However, when macroscopic examination was required to detect lesions prior to histologic sampling (e.g., skin or mammary tumors), or when lesions could have appeared at multiple sites (e.g., lymphomas), the denominators consist of the numbers of animals necropsied.

The purpose of the statistical analyses of tumor incidence is to determine whether animals receiving the test chemical developed a

significantly higher proportion of tumors than did the control As a part of these analyses, the one-tailed Fisher animals. exact test (Cox, 1970) was used to compare the tumor incidence of a control group with that of a group of treated animals at each dose level. When results for a number of treated groups (k) are compared simultaneously with those for a control group, a correction to ensure an overall significance level of 0.05 may be made. The Bonferroni inequality (Miller, 1966) requires that the P value for any comparison be less than or equal to 0.05/k. In cases where this correction was used, it is discussed in the narrative section. It is not, however, presented in the tables, where the Fisher exact P values are shown.

The Cochran-Armitage test for linear trend in proportions, with continuity correction (Armitage, 1971), was also used. Under the assumption of a linear trend, this test determines if the slope of the dose-response curve is different from zero at the onetailed 0.05 level of significance. Unless otherwise noted, the direction of the significant trend is a positive dose relationship. This method also provides a two-tailed test of departure from linear trend.

A time-adjusted analysis was applied when numerous early deaths resulted from causes that were not associated with the formation of tumors. In this analysis, deaths that occurred before the

first tumor was observed were excluded by basing the statistical tests on animals that survived at least 52 weeks, unless a tumor was found at the anatomic site of interest before week 52. When such an early tumor was found, comparisons were based exclusively on animals that survived at least as long as the animal in which the first tumor was found. Once this reduced set of data was obtained, the standard procedures for analyses of the incidence of tumors (Fisher exact tests, Cochran-Armitage tests, etc.) were followed.

When appropriate, life-table methods were used to analyze the incidence of tumors. Curves of the proportions surviving without an observed tumor were computed as in Saffiotti et al. (1972). The week during which animals died naturally or were sacrificed was entered as the time point of tumor observation. Cox's methods of comparing these curves were used for two groups; Tarone's extension to testing for linear trend was used for three groups. The statistical tests for the incidence of tumors which used life-table methods were one-tailed and, unless otherwise noted, in the direction of a positive dose relationship. Significant departures from linearity (P < 0.05, two-tailed test) were also noted.

The approximate 95 percent confidence interval for the relative risk of each treated group compared to its control was calculated

from the exact interval on the odds ratio (Gart, 1971). The relative risk is defined as p_t/p_c where p_t is the true binomial probability of the incidence of a specific type of tumor in a treated group of animals and p_c is the true probability of the spontaneous incidence of the same type of tumor in a control group. The hypothesis of equality between the true proportion of a specific tumor in a treated group and the proportion in a control group corresponds to a relative risk of unity. Values in excess of unity represent the condition of a larger proportion in the treated group than in the control.

The lower and upper limits of the confidence interval of the relative risk have been included in the tables of statistical the limits is that The interpretation of analyses. in approximately 95% of a large number of identical experiments, the true ratio of the risk in a treated group of animals to that in a control group would be within the interval calculated from the experiment. When the lower limit of the confidence interval is greater than one, it can be inferred that a statistically significant result (a P < 0.025 one-tailed test when the control incidence is not zero, P < 0.050 when the control incidence is zero) has occurred. When the lower limit is less than unity, but the upper limit is greater than unity, the lower limit indicates the absence of a significant result while the upper limit

indicates that there is a theoretical possibility of the induction of tumors by the test chemical, which could not be detected under the conditions of this test.

III. <u>RESULTS - RATS</u>

A. Body Weights and Clinical Signs (Rats)

Mean body weights were generally comparable for treated and control rats of both sexes throughout the study (figure 1). During the first 16 weeks, the treated animals were generally comparable to the controls in appearance and behavior, with the exception of the high-dose females. Beginning in week 16, convulsions were observed in three high-dose females, and by week 24 convulsions were observed in a few animals in the high-dose male and low- and high-dose female groups. At week 28, all high-dose females appeared to be hyperactive. Concentrations of photodieldrin in feed were lowered for both high- and low-dose females at week 30.

During the second year of the study, various clinical signs including epistaxis, dermatitis, alopecia, rough hair coats, loss of weight, pale mucous membranes, tachypnea, hematuria, convulsions, hyperactivity, and abdominal distention were noted with increasing frequency in the treated groups.

B. <u>Survival (Rats)</u>

The Kaplan and Meier curves estimating the probabilities of survival for male and female rats fed photodieldrin in the diet




Figure 1. Growth Curves for Rats Fed Photodieldrin in the Diet

at the doses of this experiment, together with those of the controls, are shown in figure 2. The Tarone test results were not significant in either sex at the 0.05 level for positive dose-related trend in mortality over the period. In male rats, 46% of the high-dose group, 48% of the low-dose group, and 20% of the matched controls lived to the end of the study. Survival was longer in female rats than in the males. Sixty percent of the high-dose females, 62% of the low-dose females, and 70% of the matched controls lived to termination of the study. A sufficient number of animals were available for meaningful statistical analyses of the incidence of late-developing tumors.

C. Pathology (Rats)

Histopathologic findings on neoplasms in rats are summarized in Appendix A, tables Al and A2; findings on nonneoplastic lesions are summarized in Appendix C, tables Cl and C2.

Neoplastic, degenerative, inflammatory, and proliferative lesions were encountered in both treated and control rats. The nonneoplastic lesions occurred infrequently or approximately as often among treated rats as among control rats.

Benign and malignant tumors of the pituitary gland occurred in 8/42 low-dose males and 7/46 high-dose males; benign tumors of the pituitary appeared in 5/48 low-dose females and 8/39 high-




Figure 2. Survival Curves for Rats Fed Photodieldrin in the Diet

dose females. Benign and malignant tumors of the mammary gland occurred in 7/50 low-dose females and 10/49 high-dose females. These pituitary and mammary gland tumors were not found in rats of the matched-control groups. The remaining neoplastic lesions occurred with a random distribution and with a frequency in the treated rats similar to that in the controls.

With the exception of the tumors of the pituitary and mammary gland, the neoplastic lesions observed in rats occurred sporadically or with approximately equal frequency in treated animals and in controls. However, spontaneous tumors of the pituitary gland and mammary gland may occur at high incidences in the female Osborne-Mendel rat. Therefore, in the judgment of the pathologists, it is unlikely that photodieldrin was responsible for the induction of these tumors.

D. Statistical Analyses of Results (Rats)

Tables El and E2 in Appendix E contain the statistical analyses of the incidences of those specific primary tumors that were observed in at least 5% of one or more treated groups of either sex.

In female rats, when the incidences of papillary adenoma, papillary adenocarcinoma, and follicular-cell adenoma of the thyroid are grouped, the Fisher exact test shows that the incidence of these combined tumors in the low-dose group is significantly higher than that in the pooled controls (P = 0.022). In male rats, follicular-cell adenoma was observed in one low-dose and one high-dose animal, and papillary adenocarcinoma was found in one high-dose animal. Experimental results for the combined group of papillary adenoma, papillary adenocarcinoma, and follicular-cell adenoma compiled to date from historical-control groups at this laboratory in the bioassay program indicate a spontaneous rate of less than 2% in females and 5% in males. These rates are not significantly different from those seen in the treated groups of this bioassay.

The combined incidence of adenoma and fibroadenoma of the mammary gland in female high-dose rats was double that in the low-dose animals (low-dose 5/50, high-dose 10/49), and no incidence was observed in the matched-control group; however, 8/72 (11%) were observed in the pooled-control group. The Cochran-Armitage test has a marginal significance using matched controls (P = 0.039), but this positive finding is not confirmed by the Fisher exact test results for either the low- or high-dose group or by the tests made using the pooled controls. The historical controls have an incidence of 42/235 (18%). Thus, the incidence in the matched-control group is lower than expected, and statistical significance may have occurred because of this low incidence

rather than the effect of the chemical. In male rats, no fibroadenoma or adenoma was observed. It is questionable whether tumors in the mammary glands of rats are associated with treatment.

Three hemangiomas were observed in the male high-dose group. The Cochran-Armitage test has a probability level of 0.021 when the pooled-control group is used, but this positive result is not supported by the Fisher exact test results, which show that the incidence in the high-dose group is not significant. When the Cochran-Armitage test result is based on the incidence in only one group, and this incidence has minimal significance, the trend analysis result is questionable. Two of the hemangiomas were observed in the spleen and one in subcutaneous tissue. Historical controls indicate a 0/240 incidence in male rats of this strain. There were no hemangiomas in the female rats.

Time-adjusted analyses, based on animals that lived beyond 52 weeks, performed on the incidence of chromophobe adenoma of the pituitary in male rats were not significant. When tumors are grouped for statistical analysis, as in adenoma and fibroadenoma of the mammary gland in female rats, the incidences of the individual components are not included in tables El and E2; however, a list of the incidences of each type of tumor is provided in Appendix A, tables Al and A2.

IV. <u>RESULTS - MICE</u>

A. Body Weights and Clinical Signs (Mice)

Mean body weights were comparable for treated and control groups of both male and female mice throughout the study (figure 3). During the first year of the study, the treated animals were generally comparable to the controls in appearance and behavior. During this period, some loss of weight and a few cases of alopecia were noted. During the second year of the study, other clinical signs including discolored hair coats, alopecia, and abdominal distention were observed with an increasing frequency in treated groups. Hyperexcitability was noted in most of the treated males from weeks 65 and 66 to the end of the study.

B. Survival (Mice)

The Kaplan and Meier curves estimating the probabilities of survival for male and female mice fed photodieldrin in the diet at the doses of this experiment, together with those of the controls, are shown in figure 4. The separate control groups for the high-dose group and the low-dose group for each sex are combined and designated matched controls for survival analyses. In male mice, the Tarone test result for positive dose-related trend in mortality over the period is not significant. Ninety percent of the matched controls, 90% of the high-dose group, and




Figure 3. Growth Curves for Mice Fed Photodieldrin in the Diet




Figure 4. Survival Curves for Mice Fed Photodieldrin in the Diet

78% of the low-dose group lived to the end of the study. In females, the Tarone test has a probability level of 0.039, and over 80% of all the animals survived to termination of the study. A sufficient number of animals of both sexes were available for meaningful statistical analyses of the incidences of latedeveloping tumors.

C. Pathology (Mice)

Histopathologic findings on neoplasms in mice are summarized in Appendix B, tables Bl and B2; findings on nonneoplastic lesions are summarized in Appendix D, tables Dl and D2.

A variety of neoplasms occurred both in the control and treated groups. These neoplasms occurred with approximately equal frequency in treated and control mice or appeared in insignificant numbers. These lesions, however, are not uncommon in this strain of mouse independent of any treatment.

In addition to the neoplastic lesions, a number of degenerative, proliferative, and inflammatory changes were encountered also in animals of the treated and control groups. These nonneoplastic lesions are commonly seen in aged B6C3F1 mice.

In the judgment of the pathologists, there was no definitive evidence of the carcinogenicity of photodieldrin in mice.

D. Statistical Analyses of Results (Mice)

Tables F1 and F2 in Appendix F contain the statistical analyses of the incidences of those specific primary tumors that were observed in at least 5% of one or more treated groups of either sex.

In neither sex does the incidence of any specific tumor show a statistically significant result. When the liver tumors in male mice are grouped for analysis (as in neoplastic nodules and hepatocellular carcinoma) the results are not significant. The incidence of neoplastic nodules, alone, is not included in table F1, since neither the low-dose nor the high-dose group has an incidence greater than 5%. A list of the incidences of each type of tumor is provided in Appendix B, tables B1 and B2.

In each of the 95% confidence intervals of relative risk, shown in the tables, the value of one is included; this indicates the negative aspects of the results. It should also be noted that each of the intervals has an upper limit greater than one, indicating the theoretical possibility of the induction of tumors by this chemical, which could not be detected under the conditions of this test.

V. DISCUSSION

In this bioassay of photodieldrin, mean body weights were generally comparable for treated and control rats of both sexes and also for treated and control mice of both sexes. However, hyperexcitability and convulsions were observed in treated male and female rats and in male mice. This mode of toxicity, i.e., stimulation of the central and peripheral nervous system, is similar to that of the parent chemical, dieldrin, and other related organochlorine pesticides (Brooks, 1975). Although less than 50% of the treated male rats lived until termination of the study, survival among controls was also poor; mortality rates in either sex of either species were not affected by treatment.

In rats, benign tumors (adenoma and fibroadenoma) of the mammary gland in females showed a dose-related trend (P = 0.039) compared with matched controls, but not with pooled controls (pooled controls 8/72, matched controls 0/9, low-dose 5/50, high-dose 10/49). In addition, two other low-dose females had adenocarcinomas of the mammary gland. The incidences of these tumors in either of the treated groups were not significantly higher than those in the control groups using either matched or pooled controls, and thus, their occurrence cannot clearly be associated with treatment.

Three papillary and follicular-cell adenomas and one papillary adenocarcinoma of the thyroid occurred in the low-dose females, giving a statistically significant increase over the pooled controls (P = 0.022), but these thyroid tumors did not occur in the high-dose animals. The dose-related trend was not statistically significant using either pooled or matched controls, and the incidence in the low-dose group is not greater than that in the historical controls. Thus, these lesions are not considered to be related to treatment.

The incidence of hemangiomas in male rats showed a statistically significant dose-related trend (P = 0.021) using pooled controls, but the direct comparison of the three hemangiomas in the highdose group with the pooled-control group was not statistically significant. In addition, three hemangiomas is a low number, and the tumors occurred in more than one anatomic site (two in the spleen, one in subcutaneous tissue). Thus, the hemangiomas in male rats are not considered to be related to treatment of the animals with photodieldrin.

In mice, there were no tumors that were statistically significant in treated groups of either sex.

In another bioassay, dieldrin was fed to mice at 2.5 and 5 ppm (NCI, 1977). In that study, hepatocellular carcinomas were

associated with treatment with dieldrin in male mice. The doses of dieldrin (2.5 and 5 ppm) were 7.8 times greater than the doses of photodieldrin, (0.32 and 0.64 ppm) used in the present study, which were not found to be associated with tumors of the liver in mice.

It is concluded that under the conditions of this bioassay, photodieldrin was not carcinogenic for Osborne-Mendel rats or B6C3F1 mice. .

VI. BIBLIOGRAPHY

- Armitage, P., <u>Statistical Methods in Medical Research</u>, J. Wiley & Sons, Inc., New York, 1971, pp. 362-365.
- Berenblum, I., ed., Carcinogenicity Testing: <u>A Report of the</u> <u>Panel of Carcinogenicity of the Cancer Research Commission</u> <u>of UICC</u>, Vol. 2, International Union Against Cancer, Geneva, 1969.
- Brooks, G. T., <u>Chlorinated Insecticides</u>, <u>Vol.</u> <u>2</u>. CRC Press, Inc., Cleveland, Ohio, 1975, pp. 68-100 and 119-139.
- Chau, A. S. Y., Rosen, J. D., and Cochrane, W. P., Synthesis of known and suspected environmental products of heptachlor and chlordane. <u>Bull. Environ. Contam. Toxicol.</u> <u>6</u> (3):225-230, 1971.
- Cox, D. R., Regression models and life tables. <u>J. R. Statist.</u> <u>Soc. B34</u>:187-220, 1972.
- Cox, D. R., <u>Analysis of Binary Data</u>, Methuen & Co., Ltd., London, 1970, pp. 48-52.
- Gart, J. J., The comparison of proportions: a review of significance tests, confidence limits and adjustments for stratification. <u>Rev. Int. Stat. Inst.</u> 39:148-169, 1971.
- Kaplan, E. L. and Meier, P., Nonparametric estimation from incomplete observations. <u>J. Amer. Statist. Assoc.</u> <u>53</u>:457-481, 1958.
- Linhart, M. S., Cooper, J. A., Martin, R. L., Page, N. P., and Peters, J. A., Carcinogenesis bioassay data system. <u>Comp.</u> <u>and Biomed. Res.</u> 7:230-248, 1974.
- Matsumura, F., Degradation of pesticide residues in the environment. In: <u>Environmental Pollution by Pesticides</u>, Edwards, C. A., ed., Plenum, New York, 1973, pp. 494-512.
- Matsumura, F., Patil, K. C., and Boush, G. M., Formation of "Photodieldrin" by microorganisms. <u>Science</u> 170:1206-1207, 1970.

- Miller, R. G., Jr., <u>Simultaneous Statistical Inference</u>, McGraw-Hill Book Co., New York, 1966, pp. 6-10.
- NCI, Bioassays of aldrin and dieldrin for possible carcinogenicity, Technical Report No. 21, DHEW Publication 77-821.
- Saffiotti, U., Montesano, R., Sellakumar, A. R., Cefis, F., and Kaufman, D. G., Respiratory tract carcinogenesis in hamsters induced by different numbers of administrations of benzo(a)pyrene and ferric oxide. <u>Cancer Res</u> <u>32</u>:1073-1081, 1972.
- Tarone, R. E., Tests for trend in life table analysis. Biometrika 62:679-682, 1975.

APPENDIX A

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN

RATS FED PHOTODIELDRIN IN THE DIET

.

TABLE A1.

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE **RATS FED PHOTODIELDRIN IN THE DIET**

	CONTROL	LOW DOSE	HIGH DOSE
NIMAIS INITIAILY IN STUDY	10	50	50
NIMALS NECROPSIED	10	48	50
NIMAIS EXAMINED HISTOPATHOLOGICALLY	10	48	49
NTEGUMENTARY SYSTEM			
*SUBCUT TISSUE	(12)	(48)	(50)
SARCOMA, NOS Hemangtoma		1 (2%)	1 (2%
HERANG LONA			1 (2%
ESPIFATORY SYSTEM			
*LUNG	(10)	(48)	(49)
C-CELL CARCINOMA, METASTATIC MIXED TUMOR, METASTATIC		1 (2%) 1 (2%)	
EMATOPOISTIC SYSTEM			
*MULTIPLE ORGANS	(10)	(48)	(50)
MALIG.LYMPHOMA, LYMPHOCYTIC TYPE	()	1 (2%)	(20)
IYMPHOCYTIC IFUKENTA		1 (2%)	
*SPLEEN	(9)	(48)	(47)
PIBPOSARCOMA HEMANGIONA		1 (2%)	2 /h#
ANGIONA	1 (11%)		2 (4%
TRCUIATORY SYSTEM			
N C N F			
IGPSTIVE SYSTEM			
41 IVPP	(10)	(47)	(49)
NEOPLASTIC NODULF			1 (2%
*PANCREAS	(10)	(42)	(45)
SAPCOMA, NOS, METASTATIC			1 (2%

	CONTROL	LOW DOSE	HIGH DOSE
PINAPY SYSTEM			
#KTDNEY	(1?)	(46)	(49)
MIXED TUMOR, MALIGNANT † HAMARTOMA	1 (10%)	2 (4%)	
T BAGADIONA			
NDOCFINE SYSIFM			
#PITUTTARY	(5)	(42)	(46)
CAPCINOMA, NOS		2 (5%)	1 (2%)
ADENOCAECINOMA, NOS			1 (2%)
CHROMOPHOBE ADENOMA		6 (14%)	5 (11%)
SARCOMA, NOS			1 (2%)
#ADPENAL	(8)	(42)	(49)
COPTICAL CAPCINOMA		1 (201)	1 (2%)
PHEOCHPOMOCYTOMA		1 (2%)	
#THYROID	(9)	(39)	(42)
PAPILLARY ADENOCAPCINOMA			1 (2%)
FOLITCULAR-CELL ADENOMA C-CELL ADENOMA		1 (3%), 3 (8%)	1 (2%) 1 (2%)
C-CELL CARCINONA		1 (3%)	(2%)
		(* 2)	145
*PANCREATIC ISLETS ISLFT-CELL ADENCMA	(10) 1 (19%)	(42)	(45)
EPRODUCTIVE SYSTEM			
*MAMMARY GLAND	(10)	(48)	(50)
PAPILLARY ADENOCARCINCMA			1 (2%)
FIBROMA		1 (2%)	
*TESTIS	(10)	(46)	(49)
INTERSTITIAL-CFLL TUMCR	1 (10%)	1 (2%)	
IER VOUS SYSTEM			
NONE			
PECIAL SENSE ORGANS			
NONF	و مارد کرد. می بر بر بر در مرجد مرجد م	ر است میں نامی جو میں میں میں میں میں در مرد میں میں اور اور ا	مع هارج (مطالبة فالأحاد مع هو مع بيد عبد .

TABLE A1. MALE RATS: NEOPLASMS (CONTINUED)

* NUMBER OF ANIMALS NECROFSIED

† This is considered to be a benign form of the malignant mixed tumor of the kidney and consists of lipocytes, tubular structures, and fibroblasts in varying proportions.

	CONTROL	LOW DOSE	HIGH DOSE
MUSCUTOSKELETAL SYSTEM			
*SKEIPTAL MUSCIE SARCOMA, NOS	(1^)	(48) 1 (2%)	(50)
BODY CAVITIES			
NONF			
ALL OTHER SYSTEMS			
*MULTIPLE ORGANS FIBROUS PISTICCYTOMA, MALIGNANT IFTOMYOSARCOMA	(10)	(43) 1 (2%) 1 (2%)	(50)
ANIMAI DISPOSITION SUMMARY			
ANIMALS INITIALLY IN STUDY	10	50	50
NATURAL DEATH@	2	13	11
MORTBUND SACPIFICR Scheduled sacrificr Accidentally Killed	5	13	16
TFFMINAL SACRIFICE ANIMAL MISSING	2	24	23

TABLE A1. MALE RATS: NEOPLASMS (CONTINUED)

* NUMBER OF ANTMALS WITH TISSUF EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSE
UMCR SUMMARY			
TOTAL ANIMALS WITH PPIMARY TUMCPS* TOTAL PPIMARY TUMORS	4 4	20 25	15 18
TOTAL ANIMALS WITH BENIGN TUMORS FOTAL ETNIGN TUMOPS	4 4	11 13	10 10
TOTAL ANIMALS WITH MALIGNANT TUMORS TOTAL MALIGNANT TUMORS		11 12	777
TOTAL ANIMPLS WITH SECONDARY TUMOPS# TOTAL SECONDARY TUMORS		2 2	1 1
TOTAL ANTMALS WITH TUMOPS UNCERTAIN- BENIGN OF MALIGNANT TOTAL UNCEPTAIN TUMORS			1 1
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PHIMAPY OR METASTATIC TOTAL UNCEPTAIN TUMORS			

TABLE A1. MALE RATS: NEOPLASMS (CONTINUED)

SECONDARY TUMORS: METASTATIC TUMOPS OF TUMOPS INVASIVE INTO AN ADJACENT ORGAN

TABLE A2.

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS FED PHOTODIELDRIN IN THE DIET

	CONTROL	LOW DOSE	HIGH DOSE
NIMALS INITIALLY IN STUDY NNIMALS NECEOPSIED NNIMALS EXAMINED HISTOPATHOLOGICALLY	10 9 9	50 50 50	50 49 48
NTEGUMENTARY SYSTEM			
NONF			
ESPIRATORY SYSTEM			
NCNE			
FMATOPCIEIIC SYSTEM			
*MUITIPLE ORGANS MALIG.LYMPHOMA, LYMPHOCYTIC TYPE	(9)	(50)	(49) 1 (2%
TPCULATORY SYSTEM			
#HRART/VENTRICLE FIBRCMA	(9) 1 (11%)	(49)	(47)
IGESTIVE SYSTEM			
#LIVFP HEPATOCEILULAR CARCINCMA	(9)	(49) 1 (2%)	(46)
#STOMACH LEIOMYCMA	(9)	(46) 1 (2%)	(46)
PINDFY SYSTEM			
#KTONEY CAPCINOMA,NOS	(٩)	(49)	(48) <u>1 (2</u> %)

* NUMBER OF ANIMALS NECROPSIEL

	CONTROL	LOW DOSE	HIGH DOSE
NDOCRINE SYSTEM			
<pre>#PITUTTAPY ADENCMA, NOS CHROMOPHOBF ADENOMA</pre>	(8)	(48) 1 (2%) 4 (8%)	(39) 8 (21%)
#ADEFNAI COPTICAL ADENOMA	(<i>è</i>)	(48) 1 (2%)	(43)
*THYPOID PAPILLARY ADENOMA PAPILLARY ADENOMA FOLLICUIAR-CELL ADENOMA	(9)	(43) 2 (5%) 1 (2%) 1 (2%) 2 (5%)	(39)
C-CELL ADENOMA C-CELL CARCINOMA		2 (5%)	1 (3%) 1 (3%)
*PANCEBATIC ISLETS ISLET-CELL ADENCMA	(9)	(49)	(42) 2 (5%)
PPRODUCTIVE SYSTEM			
*MAMMARY GLAND ADENCMA, NOS ADENOCAPCINOMA, NOS FTBROMA	(9)	(59) 2 (4%) 5 (10%)	(49) 1 (2%) 1 (2%)
FIBROADENOMA #UTEPUS ENDOMETRIAL STRCMAL PCLYP	(6) 1 (17%)	(42) 5 (12%)	9 (18% (37) 6 (16%
NERVOUS SYSTEM			
NGNF			
SPECIAL SENSE ORGANS			
NCNE			
USCULOSKELETAL SYSTEM			
NONF			
CDY CAVITIES			
NCNE	و ها چه ها ها و مو و این و هاید. مو و و ا		

TABLE A2. FEMALE RATS: NEOPLASMS (CONTINUED)

50	50
3	8
15	12
31	30
31	3.0
20	26
26	31
18	24
22	28
4	3
4	3

TABLE A2. FEMALE RATS: NEOPLASMS (CONTINUED)

APPENDIX B

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MICE FED PHOTODIELDRIN IN THE DIET

TABLE B1.

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE FED PHOTODIELDRIN IN THE DIET

	LOW DOSE CONTROL	HIGH DOSE CONTROL	LOW DOSE	HIGH DOSE
ANIMAIS INITIALLY IN STUDY	10	10 10	50	50
ANIMAIS NECROPSIED ANIMAIS EXAMINED HISTOFATHOLOGICALLY	10	10 10	47 47	49 49
ANIMALS CARENED RESTORATIONOGICALLI	•		4 <i>;</i>	
INTEGUMPNTARY SYSTEM				
NONE				
RESPIRATORY SYSTEM				
#1_U NG	(10)	(19)	(47)	(49)
AIVECLAR/BRONCHIOLAP ADENCMA			1 (2%)	4 (8 %)
HEMATOPOIETIC SYSTEM				
*MULTIPLE ORGANS	(10)	(10)	(47)	(49)
NALIG.LYMPHOMA, HISTIOCYTIC TYPF			1 (2%)	
CTRCHIATORY SYSTEM				
NONF				
LIGESTIVE SYSTEM				
#LIVER	(10)	(9)	(47)	(47)
NFOPLASTIC NODULE HEPATOCELLULAR CARCINOMA	3 (30%)		10 (21%)	1 (2%) 9 (19%)
HEMANGTOMA			1 (2%)	
URINARY SYSTEM				
NCNE				
INDOCRINE SYSTEM				
NONE				

* NUMBER OF ANIMALS NECFOPSIED

TABLE B1. MALE MICE: NEOPLASMS (CONTINUED)

	LOW DOSE CONTROL	HIGH DOSE CONTROL	LOW DOSE	HIGH DOSE
REPRODUCTIVE SYSTEM				
#TESTIS HEMANGIOMA	(ġ)	(10)	(46) 1 (2系)	(47)
NTRVOUS SYSTEM				
NONE				
SPECIAL SENSE ORGANS				
*EYE/LNCPIMAL GIAND Paptilary cystadencma, nos	(1^)	(19)	(47)	(49) 1 (25
MUSCULOSKELETAL SYSTEM				
NCNE				
BODY CAVITIES				
NONE				
ALL CTHYP SYSTEMS				
NONF				
ANIMAL DISPOSITION SUMMARY				
ANIMALS INITIALLY 'N STUDY NATURAL DEATHO MORIBUND SACRIFICE SCHEDULED SACRIFICE	2	10	50 6 5	50 1 4
ACCIDENTALIY KILIED TEPMINAL SACRIFICE Animal Missing	в	10	39	45
1 INCLUDES AUTOLYZEC ANIMALS				

TABLE B1. MALE MICE: NEOPLASMS (CONTINUED)

14	13
14	15
3 3	5 5
11 11	9 9
	1 1
IMORS	3 11 11

TABLE B2.

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE FED PHOTODIELDRIN IN THE DIET

	LOW DOSE CONTROL	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STULY ANIMALS NECROFSIED ANIMALS FXAMINED HISTOPATHOLOGICALLY	10 10 10	10 10 10 10	5) 49 49	50 49 49
INTEGUMENTAFY SYSTEM				
*SUBCUT TISSUE HEMANGIONA	(10)	(19)	(49) 1 (2 %)	
RESPIRATORY SYSTEM				
#IUNG AIVECLAR/BFONCHIOLAR ADENCMA	(10) 1 (19%)	(1^)	(48)	(48) 2 (4%)
HEMATOPOIETIC SYSTEM				
MULTIPLE ORGANS MALIGNANT LYMPHOMA, NOS MALTG.LYMPHONA, LYMPHOCYIIC TYPF NALIG.LYMPHOMA, HISTIOCYTIC TYPE		(10) 1 (10%) 1 (10%)		(49) 1 (2 3 (6*
CIRCUINTORY SYSTEM				
NCNF				
DIGPSTIVE SYSTEM				
<pre>#ITVFP HFPATOCFILULAR CARCINOMA</pre>	(9)	(1^)	(43)	(47) 1 (2%)
URTNARY SYSTEM				
NCNF				
ENDOCRINE SYSTEM				
NCNE				

* NUMPER OF ANIMALS NECROPSIED

TABLE B2. FEMALE MICE: NEOPLASMS (CONTINUED)

	LOW DOSE CONTROL	HIGH DOSE CONTROL	LOW DOSE	HIGH DOSE
REPRODUCTIVE SYSTEM				
*MAMMARY GIAND HAMAPICMA	(10)	(10)	(49) 1 (2%)	(4 ^q)
#OVARY Cystadenoma, nos	(9)	(8)	(45)	(46) 1 (21
NFRVOUS SYSTEM				
NONE				
SPECTAL SENSE OPGANS				
NCNF				
MUSCUIOSKFLETAI SYSIPM				
NCNE				
ECDY CAVITIES				
NONE				
ALL OTHER SYSTEMS				
NCNF				
ANIMAI DISECSITICN SUMMARY				
ANIMALS INITIALLY IN STUDY NATURAL DEATHƏ Moribund Sacrifice Scheddipd Sacrificf	10	10	50 3 1	50 3 5
ACCIDENTALLY KILLER TERNINAL SACEIFICE ANIMAL HISSING	10	10	46	42
INCLUDES AUTOLYZED ANIMALS	و و بن و و بن از			

NUMBER OF ANIMALS WITH TISSUE FXAMINED MTCROSCOPICALLY # NUMBER OF ANIMALS NECROPSIED

TABLE B2. FEMALE MICE: NEOPLASMS (CONTINUED)

		HIGH DOSE CONTROL	LOW DOSE	HIGH DOSE
TUMCE SUMMARY				
TOTAL ANIMALS WITH PPIMARY TUMORS* TOTAL PRIMARY TUMORS	1 1	2 2	3 3	8 8
TOTAL ANIMALS WITH BENIGN TUMORS TOTAL EENIGN TUMORS	1		2 2	3 3
TOTAL ANIMALS WITH MAIIGNANT TUMORS TOTAL MALIGNANT TUMORS		2 2	1 1	5
TOTAL ANIMALS WITH SECONDARY TUMORS# TOTAL SECONDARY TUMORS	:			
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT TOTAL UNCEPTAIN TUMORS				
TCTAL ANIMALS WITH TUMORS UNCERTAIN- FRIMAPY CP METASTATIC TOTAL UNCEPTAIN TUMORS				
* PRIMARY TUMORS: ALL TUMORS EXCEPT SE # SECONDARY TUMORS; METASTATIC TUMORS			DJACENT ORGAN	

APPENDIX C

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS

IN RATS FED PHOTODIELDRIN IN THE DIET

.

TABLE C1.

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS FED PHOTODIELDRIN IN THE DIET

	CONTROL	LOW DOSE	HIGH DOSE	
NIMALS INITIALLY IN STUDY	10	50	50	
NTMATS NECROPSTED	10	48	50	
NIMALS EXAMINED HISTOPATHOLOGICALLY	10	48	49	
NTEGUMENTARY SYSTEM				
*SKIN	(10)	(48)	(50)	
UICER, NOS		1 (2%)		
INFLAMMATION, FOCAI GRANULOMATOU		1 (2%)		
ESPIRATORY SYSTEM				
#LUNG	(19)	(48)	(49)	
EMPHYSEMA, NOS		2 (4%)		
ATELECTASIS		1 (2%)		
PNEUMONIA, CHRONIC MURINE		1 (2%)		
#LUNG/ALVEOLI	(10)	(48)	(49)	
EMPHYSEMA, NOS		3 (6%)	1 (2%)	
EMATOPOIETIC SYSTEM				
#SPIEEN	(9)	(48)	(47)	
CONGESTION, NOS			1 (2%	
HEMORRHAGE		1 (24)	1 (2%	
INFLAMMATION, CHRONIC FOCAL PIBROSIS, FOCAL		1 (2%) 1 (2%)		
HEMOSTDEROSIS		1 (2%)	1 (2%	
IPCULATORY SYSTEM				
#HEART	(10)	(117)	(1) (1)	
DEGENERATION PARENCHYMATOUS	(10)	(47)	(48) 1 (2%)	
DEGENERATION, HYDROPIC			1 (2%	
HEART/ATRIUM	'(10)	(47)	(48)	
THROMBOSIS, NOS		1 (25)	ينبي بين جاي كان بر يون.	

.

	CONTROL	LOW DOSE	HIGH DOSE
#ENDOCAEDIUM FIBPOSIS, FOCAL	(10)	(47) 1 (2%)	(48)
*AORTA THROMBOSIS, NOS SCLEROSIS MEDTAL CALCIFICATION CALCIFICATTON, NOS	(1^)	(4¤) _	(50) 1 (2%) 1 (2%) 1 (2%) 1 (2%)
DIGESTIVP SYSTEM			
#LIVER DFGENERATION PAPENCHYMATOUS METAMORPHOSIS FATTY CYTOLOGIC DEGENERATION ANGIECTASIS	(10) 1 (10%) 1 (10%) 1 (10%)	(47) 3 (6%) 5 (11%) 1 (2%) 3 (6%)	(49) 2 (4%) 9 (18%) 5 (10%)
*BILF DUCT HYPERDIASIA, NOS	(10)	(48) 1 (2 %)	(50)
#PANCPEAS PERIARTERITIS Necrosis, Fat	(10)	(42) 1 (2%)	(45) 1 (2 %)
*STOMACH ULCFR, NOS CALCIFICATION, DYSTROPHIC	(10) 3 (30%)	(45) 1 (2 %)	(46)
*GASTRIC MUCOSA EROSION NFCROSIS, FOCAL	(10)	(45)	(46) 1 (2%) 1 (2%)
URINARY SYSTEM			
<pre>#KIDNEY HYDPONEPHROSIS GLOMERULONEPHRITIS, NOS INPLAMMATION, CHRONIC INFLAMMATION, CHRONIC DIFFUSE</pre>	(1º) 3 (30%) 2 (20%)	(46) 1 (2%) 4 (9%) 15 (33%)	(49) 6 (12%) 13 (27%) 1 (2%)
#KIDNEY/PEIVIS INFLAMMATION, NOS	(19)	(46)	.(49) 1 (2%)
#UPINARY BLADDER <u>INFLAMMATION, ACUTE NECROTIZING</u>	(10)	(43) <u>1 (2%)</u>	(45)

TABLE C1. MALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

TABLE C1. MALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

	CONTROL	LOW DOSE	· HIGH DOSE
HYPERPLASIA, EPITHEIIAL			1 (2%)
HIPENPERVER, Erstnalang			
ENDOCEINE SYSTEM		,	
#PITNITARY	(5)	(42)	(46)
CYST, NOS		1 (2%)	1 (2%)
MUITIPIE CYSTS		1 (2%)	
CONGESTION, NOS		1 (2%)	
HYPERPLASIA, NOS		3 (7%)	
HYPERPLASIA, CHROMOPHOBE-CEIL			1 (2%)
ANGIECTASIS	1 (20%)		1 (2%)
#ADRFNAL	(8)	(42)	(49)
NECPOSIS, HEMORPHAGIC		1 (2%)	
ANGIECTASIS			1 (2%)
#ADBENAL COPTEX	(8)	(4?)	(49)
CYST, NOS		1 (2%)	1
METAMORPHOSIS FATTY		1 (2%)	
HYPPRPLASIA, DIFFUSE		()	1 (2%)
#THYPOID	(9)	(39)	(42)
FOLLICULAR CYST, NOS	()	(33)	2 (5%)
HYPERPLASIA, FOLLICULAR-CELL	1 (11%)	5 (13%)	2 (5%)
			(25)
#PAPATHYPOID	(5)	(15)	(25)
HYPERPLASIA, NOS	1 (17%)		
REPRODUCTIVE SYSTEM			
*MAMMARY GIAND	(10)	(48)	(50)
NECPOSIS, FAT		1 (2%)	
*MAMMARY LOBULE	(10)	(49)	(50)
HYPERPLASIA, NOS	,		1 (2%)
*PROSTATE	(10)	(41)	(46)
INFLAMMATION, NCS	1 (17%)	1 (3%)	
INFLAMMATION, SUPPURATIVE	1 (10%)		
INFIAMMATION, ACUTE			1 (2%)
INFIAMMATION, ACUTE SUPPERATIVE			1 (2%)
HYPERPLASIA, NOS	1 (10%)		
*SEMINAL VFSICLE	(10)	(48)	(5^)
DEGENERATION, CYSTIC		1 (2%)	

NUMBER OF ANTMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOS
*TESTIS ATROPHY, NOS ATPOPHY, FOCAL HYPERPLASIA, INTERSTITIAL CELL		(46) 9 (20%) 1 (2%) 1 (2%)	(49) 12 (24%
NERVOUS SYSTEM			
NCNF			
SPECIAL SENSE OPGANS			
NCNE			
MUSCULOSKELETAL SYSTEM			
NCNF			
ECDY CAVITIES			
*MESENTERY	(19)	(48)	(50)
	(10) 1 (10%) 1 (10%)	(48)	(50) 3 (6%)
*MESENTERY THROMBOSIS, NOS PEPIARTERITIS	1 (10%)	(48)	
*MESENTERY Thronbosis, Nos	1 (10%)	(48)	
*MESENTERY THROMBOSIS, NOS PEPIARTERITIS AIL OTHER SYSTEMS	1 (10%)	(48)	
*MESENTERY THROMBOSIS, NOS PEPIARTERITIS ALL OTHER SYSTEMS NONE	1 (10%)	(48)	

TABLE C1. MALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

TABLE C2.

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS FED PHOTODIELDRIN IN THE DIET

	CONTROL	LOW DOSE	HIGH DOSE
NIMPLS INITIALLY IN STUDY		50	50
INTMAIS NECROPSIED	ò	50	49
ANIMALS EXAMINED HISTOPATHOLOGICAILY	9	50	48
NTEGUMENTARY SYSTEM			
NONF			
RESPIRATORY SYSTEM			
#LUNG/BRONCHIOLE	(<i>9</i>)	(50)	(47)
HYPERPLASIA, LYMPHCID		1 (2%)	
#LUNG	(9)	(50)	(47)
CONGESTION, NCS			2 (4%
HEMOREHAGE Inflammation, Focal		2 (4%)	1 (2%
*LUNG/ALVEOLI	(9)	(50)	(47)
EMPHYSENA, NOS		1 (2%)	1 (2%
ENATOPOTETIC SYSTEM			
#SPLEEN	(9)	(49)	(46)
CONGESTION, NOS		1 (2%)	
HYPOPLASTA, LYMPHOID		1 (2%)	
IRCULATORY SYSTEM			
NCNE			
CIGESTIVE SYSTEM			
#LIVER	(9)	(49)	(46)
HEMORRHAGE		1 (2%)	
LYMPHOCYTIC INFILTRATE		بیک نوازی کا سرمیا سال ود شداخاند ده به ساله	1_(2%

	CONTROL	LOW DOSE	HIGH DOSE
DEGENEEATION PARENCHYMATOUS NECEOSIS, NOS	•••••	2 (4%) 1 (2%)	
NECROSIS, FOCAL	1 (11%)		
MFTAMORPHOSIS FATTY ANGIECIASIS	1 (11%)	3 (6%) 2 (4%) -	8 (17%
#HEPATIC CAPSULF HEMOBRHAGE	(ġ)	(40)	(46) 1 (2%)
#LIVER/CENTFILOBULAP METANCEPHOSIS PATTY	(9)	(49)	(46) 1 (2%)
*RILE DUCT Hypppplasia, Nos	(<u>\</u>	(50) 2 (4%)	(49)
#PANCEPAS METAMORPHOSIS FATTY	(9)	(49) 1 (2%)	(42)
#GASTRIC MUCOSA	(9)	(46)	(46)
NECPOSIS, FOCAL		1 (2%)	
#GASTPIC FUNDUS AEPADED WCUND	(9)	(46)	(46) 1 (2%)
PINAPY SYSTEM			
#KIDNEY Cyst, NCS	(⁽ ,)	(49)	(4 <u>9</u>) 1 (2%)
GIOMERUION PPHRITIS, NOS			4 (8%)
TNPLAMMATION, NOS		1 (2%)	
INFLAMMATION, FOCAL INFLAMMATION, CHPONIC		1 (2%) 1 (2%)	
INFLAMMATION, CHRONIC FOCAL	1 (11%)	, (28)	
#KIDNEY/COPTEX MULTILOCULAR CYST	(9)	(49) 1 (2%)	(48)
*KIDNRY/PELVIS	(9)	(49)	(48)
HYPERPLASIA, EPITHELIAL	N - F	1 (2%)	
NDOCRINE SYSTEM			
*PITUITARY	(8)	(48)	(39)
CCNGESTION, NOS	2 (25%)		1 (3%)

TABLE C2. FEMALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

NUMBER OF ANTMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NFCROPSIED

CONTROL		HIGH DOS
2 (25%)	2 (4%)	2 (5%)
		1 (3%)
1 (13%)	5 (10%)	3 (8%)
(9)	(48)	(43)
	1 (2%)	
	2 (4%)	2 (5%)
		1 (2%)
	1 (2%)	
		1 (2%)
		1 (2%)
	2 (4%)	4 (9%)
(9)	(48)	(43)
		1 (2%)
		1 (2%)
a (aam)	1 (2%)	
1 (11%)	2 (49)	
	2 (4%)	
(⁹)	(43)	(39)
	1 (2%)	
(9)	(49)	(42)
1 (11%)		
(9)	(59)	(49)
	1 (2%)	
(6)	(42)	(37)
	1 (2%)	
	2 (25%) 1 (13%) (9) (9) 1 (11%) (9) (9) 1 (11%) (9) (9) (9) 1 (11%)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$

NUMBER OF ANIMALS WITH TISSUE FXAMINED MICROSCOPICALLY # NUMBER OF ANIMALS NECROPSIED

TABLE C2. FEMALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

TABLE C2. FEMALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

	CONTROL	LOW DOSE	HIGH DOSE
BCDY CAVITIES			
NCNE			
ALL OTHER SYSTEMS NONE			
SPECIAL MOFEHOLOGY SUMMARY			
NO LESION REFORTED AUTC/NECPOPSY/NO HISTO AUTOLYSTS/NO NECROPSY	3 1	12	13 1 1
* NUMBER OF ANIMALS WITH TISSUE EXAMT * NUMBER OF ANIMALS NECROPSIED	NED MICROSCOPICAT	LLY	

APPENDIX D

.

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS

IN MICE FED PHOTODIELDRIN IN THE DIET

TABLE D1.

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE FED PHOTODIELDRIN IN THE DIET

	LOW DOSE CONTROL	HIGH DOSE CONTROL	LOW DOSE	HIGH DOSE
NIMALS INITIALLY IN STUDY			50	50
NIMAIS NECEOPSIED	10	10	47	49
NIMAIS EXAMINED HISTOPATHOLOGICALLY	8	10	47	49
NTEGUMENTAPY SYSTEM				
NONE				
FSPIPATCRY SYSTEM				
#I U NG	(10)	(10)	(47)	(49)
HEMOBEHAGE		1 (10%)		
INFLAMMATION, FOCAL			1 (2%)	
HYPEFPLASIA, AIVEOLAR EPITHELIUM		1 (10%)		
FMATOPOITTIC SYSTEM				
*LYMPH NODE	(9)	(9)	(42)	(44)
INFLAMMATION, NOS				1 (2%)
#MESENTERIC L. NODÊ	(8)	(9)	(42)	(44)
INFLAMMATION, NOS				1 (2%
#SUBSCAPULAR LYMPH NO	(8)	(9)	(42)	(44)
INFARCT, NOS	(-)	(-)	,	Ì 1 (2%)
#THYMUS		(1)		
HYPEPPLASIA, LYMPHOID		1 (100%)		
CIRCULATORY SYSTEM				
NCNE				
CIGESTIVE SYSTEM				
*LIVER	(10)	(9)	(47)	(47)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICBOSCOPICALLY * NUMBER OF ANIMALS NECFOPSIED

	LOW DOSE CONTROL	HIGH DOSE CONTROL	LOW DOSE	HIGH DOSE
HYPEFFLASIA, NODULAP		3 (33%)		3 (6%
DRINARY SYSTEM				
NCNF				
NDCCPINE SYSTEM				
NCNE				
FPFODUCTIVE SYSTEM				
NCNE				
FRVCUS SYSTEM				
#BRAIN Corpora Anylacta	(9) 1 (11%)	(10) 1 (10%)	(45)	(49) 3 (6%
FECTAL SENSE OFGANS				
NONE				
USCULOSKELFTAL SYSTEM				
NGNE				
CAVITIES				
NONE				
II OTHER SYSTEMS				
NONE				
PECIAL MORPHOLOGY SUMMARY				
NO_LESION_REFORTED	4	6	32	30

TABLE D1. MALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

TABLE D1. MALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

	LOW DOSE CONTROL	HIGH DOSE CONTROL	LOW DOSE	HIGH DOSE
AUTC/NECROPSY/NC HISTO AUTOLYSIS/NO NECROPSY	2		3	1
* NUMBER OF ANIMALS WITH TISSUE E * NUMPER OF ANIMALS NTCROPSIED	XAMINED MICROSCOPI	CALLY		

TABLE D2.

.

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE FED PHOTODIELDRIN IN THE DIET

	LOW DOSE CONTROL	HIGH DOSE CONTROL	LOW DOSE	HIGH DOSE
NIMALS INITIALLY IN STUDY	10		50	50
INIMALS NECROPSIED	10	10	49	49
NIMAIS EXAMINED HISTOPATHOLOGICALLY	10	19	49	49
INTEGUMENTARY SYSTEM				
NONE				
RESPIRATORY SYSTEM				
<pre>#LUNG/BRONCHIOIE HYPP3PIASIA, LYMPHOID</pre>	(10)	(10)	(48)	(48) 1 (2 %)
#LUNG	(10)	(10)	(49)	(48)
PNEUMONIA, ASPIRATICN				1 (2%)
IEMATOPOTETIC SYSTEM				
#SPLFEN	(11)	(10) 1 (10%)	(48)	
HYPESPLASIA, LYMPHOID		1 (10%)	2 (4%)	3 (6%)
TIRCHIATORY SYSTEM				
#MYOCARDIUM	(10)	(10)	(48)	(48)
FIBRCSIS, FOCAL				1 (2%)
CIGESTIVE SYSTEM				
# <u>T</u> _ A E =	(9)	(19)	(43)	(47)
DEGENERATION PARENCHYMATOUS METAMOFEHOSIS FATTY			1 (2%)	3 (6%) 1 (2%)
HYPERPLASIA, NODULAR		1 (10%)	3 (7%)	1 (2%)
HYPERPLASIA, DIFFUSE	1 (11%)	. ,	2 (5%)	1 (2%)
HYPERPLASIA, LYMPHOID NODULAR FEGENSRATION			1 (2%) 1 (2%)	
#PANCRFAS	(10)	(10)	(47) 1 (2%)	(46)

NUMBER OF ANIMALS WITH TISSUE FXAMINED MICROSCOPICALLY
 NUMBER OF ANIMALS NECROFSIED

TABLE D2.	. FEMALE MICE: NONNEOPLASTIC LESIONS (CON	TINUED)

CONTROL	CONTROL	LOW DOSE	HIGH DOSE
(10)	(10) 1 (10%)	(48)	(48)
(10)	(10)	(48)	(48) 1 (2 %)
(")	(17)	(41)	(42) 1 (2*)
(1^)	(9)	(45)	(43) 1 (254) 3 (マダ)
2 (2^%)	2 (22%)	7 (16%)	5 (¥) 6 (149
(10)	(9)	(45) 1 (2%)	(43)
(9) 1 (11%)	(8)	(45)	(46) 1 (2%) 1 (2%)
1 (11%)	4 (50%)	8 (18%) 1 (2%)	1 (2%) 1 (2%) 2 (4%)
1 (11%)		1 (2%)	
(10)	(10)	(47)	(49) 1 (2%)
	(1^{0}) (1^{0}) (7) (1^{0}) $2 (2^{3})$ (1^{0}) (1^{0}) (9) $1 (11^{3})$ $1 (11^{3})$ $1 (11^{3})$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$

* N'MPER OF ANIMALS WITH TISSUF FXAMINED MICPOSCOPICALLY * NUMBER OF ANIMALS NECROFSIED

TABLE D2. FEMALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

		LOW DOSE	HIGH DOSE
(10)	(10)	(49)	(49) 1 (2%
4	1	23 1	24 1
	CONTROL (10)	CONTROL CONTROL	CONTROL CONTROL (10) (1?) (49) 4 1 23

APPENDIX E

ANALYSES OF THE INCIDENCE OF PRIMARY TUMORS

IN RATS FED PHOTODIELDRIN IN THE DIET

.

.

	Pooled	Matched	Low	High
Topography: Morphology	Control	Control	Dose	Dose
Pituitary: Carcinoma, NOS ^b	1/62 (2)	0/5 (0)	2/42 (5)	1/46 (2)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f			2.952	1.348
Lower Limit			0.158	0.017
Upper Limit			169.961	103.525
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.045	0.010
Upper Limit			Infinite	Infinite
Weeks to First Observed Tumor			93	106
Pituitary: Carcinoma, NOS or				
Adenocarcinoma, NOS ^b	1/62 (2)	0/5 (0)	2/42 (5)	2/46 (4)
P Values ^c ,d	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f			2.952	2.696
Lower Limit			0.158	0.144
Upper Limit			169.961	155.545
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.045	0.041
Upper Limit			Infinite	Infinite
Weeks to First Observed Tumor			93	85

(continued)				
	Pooled	Matched	Low	High
Topography: Morphology	<u>Control</u>	Control	Dose	Dose
Pituitary: Chromophobe				
Adenoma ^b	8/62 (13)	0/5 (0)	6/42 (14)	5/46 (11)
P Values ^c ,d	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f			1.107	0.842
Lower Limit			0.339	0.230
Upper Limit			3.348	2.711
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.244	0.176
Upper Limit			Infinite	Infinite
Weeks to First Observed Tumor			81	84
Thyroid: C-cell Adenoma ^b	2/65 (3)	0/9 (0)	3/39 (8)	1/42 (2)
P Values ^c ,d	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f			2.500	0.774
Lower Limit			0.299	0.013
Upper Limit			28.669	14.321
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.156	0.013
Upper Limit			Infinte	Infinite
Weeks to First Observed Tumor			57	112

	Pooled	Matched	Low	High
Topography: Morphology	Control	Control	Dose	Dose
				<u> </u>
Thyroid: C-cell Adenoma or				
Carcinoma ^b	2/65 (3)	0/9 (0)	4/39 (10)	1/42 (2)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f			3.333	0.774
Lower Limit			0.499	0.013
Upper Limit			35.249	14.321
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.242	0.013
Upper Limit			Infinite	Infinite
Weeks to First Observed Tumor			57	112
mhannaith. Deathlanna Adamasanaire				
Thyroid: Papillary Adenocarcino		0/0 (0)	1/20 (2)	2/12 /5
or Follicular-cell Adenoma ^b	0/65 (0)	0/9 (0)	1/39 (3)	2/42 (5)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f			Infinite	Infinite
Lower Limit			0.089	0.455
Upper Limit			Infinite	Infinite
opper bimic			Intinte	Intintte
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.014	0.071
Upper Limit			Infinite	Infinite
• •				
Weeks to First Observed Tumor				112

	Pooled	Matched	Low	High
Topography: Morphology	<u>Control</u>	Control	Dose	Dose
Pancreatic Islets:				
Islet-cell Adenoma ^b	3/72 (4)	1/10 (10)	0/42 (0)	0/45 (0)
P Values ^c ,d	N.S.	N.S.	N.S.	N.S.
Departure from Linear Trend ^e		P = 0.033		
Relative Risk (Pooled Control) ^f	· · · ·		0.000	0.000
Lower Limit			0.000	0.000
Upper Limit			2.840	2.659
Relative Risk (Matched Control) ^f			0.000	0.000
Lower Limit			0.000	0.000
Upper Limit			4.444	4.155
Weeks to First Observed Tumor		111		
All Sites: Hemangioma ^b	0/75 (0)	0/10 (0)	0/48 (0)	3/50 (6)
P Values ^{c,d}	P = 0.021	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f				Infinite
Lower Limit				0.895
Upper Limit				Infinite
Relative Risk (Matched Control) ^f				Infinite
Lower Limit				0.134
Upper Limit				Infinite
Weeks to First Observed Tumor				99

08

Table El. Analyses of the Incidence of Primary Tumors in Male Rats Fed Photodieldrin in the Diet^a

.

.

(continued)

^aTreated groups received doses of 5 or 10 ppm in feed.

^bNumber of tumor-bearing animals/number of animals examined at site (percent).

^CBeneath the incidence of tumors in a control group is the probability level for the Cochran-Armitage test when P < 0.05; otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a treated group is the probability level for the Fisher exact test for the comparison of that treated group with the matched-control group (*) or with the pooledcontrol group (**) when P < 0.05 for either control group; otherwise, not significant (N.S.) is indicated.

 d_A negative trend (N) indicates a lower incidence in a treated group than in a control group.

81

^eThe probability level for departure from linear trend is given when P < 0.05 for any comparison.

 $f_{\rm The}$ 95% confidence interval of the relative risk between each treated group and the specific control group.

Topography: Morphology	Pooled <u>Control</u>	Matched Control	Low Dose	High Dose
Pituitary: Chromophobe Adenoma ^b	12/62 (19)	0/8 (0)	4/48 (8)	8/39 (21)
P Values ^c ,d	N.S.	P = 0.038	N.S.	N.S.
Relative Risk (Pooled Control) ^f			0.431	1.060
Lower Limit			0.107	0.409
Upper Limit			1.319	2.534
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.178	0.543
Upper Limit			Infinite	Infinite
Weeks to First Observed Tumor			58	95
Thyroid: C-cell Adenoma ^b	1/66 (2)	0/9 (0)	2/43 (5)	1/39 (3)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f			3.070	1.692
Lower Limit			0.166	0.022
Upper Limit			176.825	129.471
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.069	0.014
Upper Limit			Infinite	Infinite
Weeks to First Observed Tumor			106	112

(continued)				
	Pooled	Matched	Low	High
Topography: Morphology	<u>Control</u>	Control	Dose	Dose
Thyroid: C-cell Adenoma				
or Carcinoma ^b	2/66 (3)	0/9 (0)	2/43 (5)	2/39 (5)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f			1.535	1.692
Lower Limit			0.114	0.127
Upper Limit			20.387	22.398
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.069	0.077
Upper Limit			Infinite	Infinite
Weeks to First Observed Tumor			106	112
Thyroid: Papillary Adenoma,				
Papillary Adenocarcinoma, or				
Follicular-cell Adenoma ^b	0/66 (0)	0/9 (0)	4/43 (9)	0/39 (0)
P Values ^{c,d}	N.S.	N.S.	P = 0.022 **	N.S.
Departure From Linear Trend ^e	P = 0.002			
Relative Risk (Pooled Control) ^f			Infinite	
Lower Limit			1.415	
Upper Limit			Infinite	
Relative Risk (Matched Control) ^f			Infinite	
Lower Limit			0.220	
Upper Limit			Infinite	
Weeks to First Observed Tumor			102	

(continued)	Pooled		T	TT / . 1
		Matched	Low	High
Topography: Morphology	Control	Control	Dose	Dose
Thyroid: Papillary Adenoma or				
Papillary Adenocarcinoma ^b	0/66 (0)	0/9 (0)	3/43 (7)	0/39 (0)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Departure From Linear Trend ^e	P = 0.007			
Relative Risk (Pooled Control) ^f			Infinite	
Lower Limit			0.920	
Upper Limit			Infinite	
Relative Risk (Matched Control) ^f			Infinite	
Lower Limit			0.142	
Upper Limit			Infinite	
Weeks to First Observed Tumor			102	
Pancreatic Islets: Islet-cell				
Adenoma ^b	1/69 (1)	0/9 (0)	0/49 (0)	2/42 (5)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f			0.000	3.286
Lower Limit			0.000	0.176
Upper Limit			26.256	189.114
Relative Risk (Matched Control) ^f				Infinite
Lower Limit				0.071
Upper Limit				Infinite
Weeks to First Observed Tumor				100

(continued)	Pooled	Matched	Low	High
Topography: Morphology	Control	Control	Dose	Dose
		0000002		
Mammary Gland: Adenoma,				
Fibroadenoma, or Adeno-				
carcinoma, NOS ^b	9/72 (13)	0/9 (0)	7/50 (14)	10/49 (20)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
		A D C		M.D.
Relative Risk (Pooled Control) ^f			1.120	1.633
Lower Limit			0.376	0.642
Upper Limit			3.137	4.180
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.396	0.622
Upper Limit			Infinite	Infinite
Weeks to First Observed Tumor			58	56
Mammary Gland: Adenoma				
or Fibroadenoma ^b	8/72 (11)	0/9 (0)	5/50 (10)	10/49 (20)
	-,,= (==)			(,
P Values ^{c,d}	N.S.	P = 0.039	N.S.	N.S.
Relative Risk (Pooled Control) ^f			0.900	1.837
Lower Limit			0.244	0.700
Upper Limit			2.920	4.945
-rr				
			Televite	Infinite
Relative Risk (Matched Control) ^f			Infinite	Infinite
Relative Risk (Matched Control) ^f Lower Limit			0.256	0.622
Relative Risk (Matched Control) ^f Lower Limit Upper Limit				

	Pooled	Matched	Low	High
Copography: Morphology	Control	<u>Control</u>	Dose	Dose
Uterus: Endometrial Stromal				
Polypb	7/67 (10)	1/6 (17)	5/42 (12)	6/37 (16)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control)	£		1.139	1.552
Lower Limit			0.303	0.459
Upper Limit			3.868	4.940
Relative Risk (Matched Control)t		0.714	0.973
Lower Limit			0.116	0.171
Upper Limit			32.973	43.453
Jeeks to First Observed Tumor		111	81	112

^aTreated groups received time-weighted average doses of 3.4 or 7.5 ppm in feed.

86

^bNumber of tumor-bearing animals/number of animals examined at site (percent).

^CBeneath the incidence of tumors in a control group is the probability level for the Cochran-Armitage test when P < 0.05; otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a treated group is the probability level for the Fisher exact test for the comparison of that treated group with the matched-control group (*) or with the pooledcontrol group (**) when P < 0.05 for either control group; otherwise, not significant (N.S.) is indicated.

^dA negative trend (N) indicates a lower incidence in a treated group than in a control group.

^eThe probability level for departure from linear trend is given when P < 0.05 for any comparison.

^fThe 95% confidence interval of the relative risk between each treated group and the specific control group.

APPENDIX F

ANALYSES OF THE INCIDENCE OF PRIMARY TUMORS

IN MICE FED PHOTODIELDRIN IN THE DIET

	Pooled	Matched	Low	High
Topography: Morphology	<u>Control</u>	Control	Dose	Dose
Lung: Alveolar/Bronchiolar				
Adenoma ^b	5/77 (6)	0/20 (0)	1/47 (2)	4/49 (8)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f			0.328	1.257
Lower Limit			0.007	0.260
Upper Limit			2.792	5.529
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.023	0.393
Upper Limit			Infinite	Infinite
Weeks to First Observed Tumor			93	81
Hematopoietic System: Lymphoma ^b	0/78 (0)	0/20 (0)	1/47 (2)	0/49 (0)
P Values ^c ,d	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f			Infinite	
Lower Limit			0.088	
Upper Limit			Infinite	
Relative Risk (Matched Control) ^f			Infinite	
Lower Limit			0.023	
Upper Limit			Infinite	
			93	

	Pooled	Matched	Low	High
Topography:Morphology	Control	Control	Dose	Dose
Liver: Hepatocellular				
Carcinoma ^b	11/76 (14)	3/18 (17)	10/47 (21)	9/47 (19)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f			1.470	1.323
Lower Limit			0.603	0.520
Upper Limit			3.484	3.219
Relative Risk (Matched Control) ^f			1.277	1.149
Lower Limit			0.388	0.336
Upper Limit			6.657	6.094
Weeks to First Observed Tumor		93	74	68
Liver: Neoplastic Nodule or				
Hepatocellular Carcinoma ^b	14/76 (18)	3/18 (17)	10/47 (21)	10/47 (21)
P Values ^c ,d	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f			1.155	1.155
Lower Limit			0.497	0.497
Upper Limit			2.540	2.540
Relative Risk (Matched Control) ^f			1.277	1.277
Lower Limit			0.388	0.388
Upper Limit			6.657	6.657

(continued)

91

^aTreated groups received doses of 0.32 or 0.64 ppm in feed.

^bNumber of tumor-bearing animals/number of animals examined at site (percent).

^CBeneath the incidence of tumors in a control group is the probability level for the Cochran-Armitage test when P < 0.05; otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a treated group is the probability level for the Fisher exact test for the comparison of that treated group with the matched-control group (*) or with the pooledcontrol group (**) when P < 0.05 for either control group; otherwise, not significant (N.S.) is indicated.

 d A negative trend (N) indicates a lower incidence in a treated group than in a control group.

^eThe probability level for departure from linear trend is given when P < 0.05 for any comparison.

^fThe 95% confidence interval of the relative risk between each treated group and the specific control group.

	Pooled	Matched	Low	High
Copography: Morphology	Control	Control	Dose	Dose
ung: Alveolar/Bronchiolar				
Adenoma ^b	2/78 (3)	1/20 (5)	0/48 (0)	2/48 (4)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
R∈lative Risk (Pooled Control) ^f			0.000	1.625
Lower Limit			0.000	0.120
Upper Limit			5.493	21.678
Relative Risk (Matched Control) ^f			0.000	0.833
Lower Limit			0.000	0.047
Upper Limit			7.780	48.155
Weeks to First Observed Tumor		93		81
Hematopoietic System: Lymphoma ^b	3/79 (4)	2/20 (10)	1/49 (2)	4/49 (8)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f			0.537	2.150
Lower Limit			0.010	0.379
Upper Limit			6.442	14.050
Relative Risk (Matched Control) ^f			0.204	0.816
Lower Limit			0.004	0.130
Upper Limit			3.754	8.603
Weeks to First Observed Tumor		92	93	88

92

.

	Pooled	Matched	Low	High
Topography: Morphology	Control	<u>Control</u>	Dose	Dose
Liver: Hepatocellular Carcinoma ^b	2/76 (3)	0/19 (0)	0/43 (0)	1/47 (2)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) f		0.000	0.809
Lower Limit			0.000	0.014
Upper Limit			5.958	15.027
Relative Risk (Matched Contro	1) ^f			Infinite
Lower Limit			-	0.022
Upper Limit				Infinite
Weeks to First Observed Tumor				93

93

^aTreated groups received doses of 0.32 or 0.64 ppm in feed.

^bNumber of tumor-bearing animals/number of animals at site (percent).

^CBeneath the incidence of tumors in a control group is the probability level for the Cochran-Armitage test when P < 0.05; otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a treated group is the probability level for the Fisher exact test for the comparison of that treated group with the matched-control group (*) or with the pooledcontrol group (**) when P < 0.05 for either control group; otherwise, not significant (N.S.) is indicated.

 d_A negative trend (N) indicates a lower incidence in a treated group than in a control group.

^eThe probability level for departure from linear trend is given when P < 0.05 for any comparison.

fThe 95% confidence interval of the relative risk between each treated group and the specific control group.

APPENDIX G

ANALYSIS OF FORMULATED DIETS FOR

CONCENTRATIONS OF PHOTODIELDRIN

APPENDIX G

Analysis of Formulated Diets for Concentrations of Photodieldrin

A 10-g sample of the diet mixture was shaken with 125 ml benzene for 16 hours, then filtered through Celite with benzene washes. The combined extracts were reduced in volume and analyzed for photodieldrin by gas-liquid chromatography (electron capture detector, 10% DC-200 on Gas Chrom Q column). Recoveries were checked with spiked samples, and external standards were used for calibrations.

Theoretical Concentrations in Diet (ppm)	No. of Samples	Sample Analytical Mean (ppm)	Coefficient of Variation (%)	Range (ppm)
0.32	10	0.32(1)	5.8%	0.29-0.35
0.64	10	0.63(8)	3.7%	0.61-0.68
2.50	9	2.51	4.2%	2.36-2.70
5.00	23	5.08	3.2%	4.80-5.50
10.00	22	9.98	4.6%	9.20-10.90

+U.S. GOVERNMENT PRINTING OFFICE: 1977-260-899:3138

.

.

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

National Institutes of Health

REPORT ON BIOASSAY OF PHOTODIELDRIN FOR POSSIBLE CARCINOGENICITY Availability

Photodieldrin has been tested for cancer-causing activity with rats and mice in the Carcinogenesis Program, Division of Cancer Cause and Prevention, National Cancer Institute. A report is available to the public.

<u>Summary</u>: A bioassay of dieldrin-free photodieldrin (synthesized by Gulf South Research Institute) for possible carcinogenicity was conducted by administering the test material in feed to Osborne-Mendel rats and B6C3F1 mice.

Groups of 50 rats of each sex were initially administered photodieldrin at one of two doses, either 5 or 10 ppm. Because of neurotoxic signs, doses in the females were reduced after 30 weeks. Total periods of treatment for low- and high-dose males and low-dose females were 80 weeks, followed by periods of 31 or 32 weeks of additional observation; the total period of treatment for the high-dose females was 59 weeks, followed by a period of additional observation of 53 weeks. The timeweighted average doses for the females were 3.4 or 7.5 ppm. Matched controls consisted of 10 untreated rats of each sex; pooled controls, used for statistical evaluation, consisted of the matched controls combined with 65 untreated male and 65 untreated female rats from similarly performed bioassays of six other test chemicals. All surviving rats were killed at 111-112 weeks. Groups of 50 mice of each sex were administered photodieldrin at one of two doses, either 0.32 or 0.64 ppm, for 80 weeks, then observed for an additional 13 weeks. Matched controls consisted of groups of 10 untreated mice of each sex at each dose; pooled controls, used for statistical evaluation, consisted of the matched controls combined with 60 untreated male and 60 untreated female mice from similarly performed bioassays of six other test chemicals. All surviving mice were killed at 93 weeks.

Mean body weights attained by low- and high-dose male and female rats and mice were essentially unaffected by photodieldrin. Convulsions and hyperactivity were noted in treated male and female rats and in male mice. Mortality rates of either sex or either species were not affected by treatment.

In rats, benign tumors (adenoma and fibroadenoma) of the mammary gland in females showed a dose-related trend (P = 0.039) compared with matched, but not pooled, controls (8/72 pooled controls, 0/9 matched controls, 5/50 low-dose, 10/49 high-dose). Adenocarcinoma of the mammary gland occurred in two additional low-dose females. The incidences of these tumors in either of the treated groups were not significantly higher than those in the control groups using either matched or pooled controls. Three papillary and follicular-cell adenomas and one papillary adenocarcinoma of the thyroid occurred in the low-dose females, giving a statistically significant increase over the pooled controls (P = 0.022), but these thyroid tumors did not occur in the high-dose animals. The doserelated trend was not statistically significant using either pooled or

- 2 -

matched controls, and the incidence in the low-dose group is not greater than that in the historical controls. In male rats, the incidence of hemangiomas showed a statistically significant dose-related trend (P = 0.021) using pooled controls, but the direct comparison of the three hemangiomas in the high-dose group with the pooled-control group was not statistically significant. Furthermore, three hemangiomas is a small number, and the tumors occurred in more than one anatomic site (two in the spleen, one in subcutaneous tissue). The occurrence of these tumors cannot clearly be associated with treatment.

In mice, there were no tumors that were statistically significant in treated groups of either sex.

It is concluded that under the conditions of this bioassay, photodieldrin was not carcinogenic for Osborne-Mendel rats or B6C3F1 mice.

Single copies of the report are available from the Office of Cancer Communications, National Cancer Institute, Building 31, Room 10A21, National Institutes of Health, Bethesda, Maryland 20014.

Dated: December 2, 1977

Director National Institutes of Health

(Catalogue of Federal Domestic Assistance Program Number 13.393, Cancer Cause and Prevention Research)



U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

FOR RELEASE IN A.M. PAPERS Friday, December 2, 1977 National Institutes of Health Office of Cancer Communications (301) 496-6641

Availability of a report on animal tests of photodieldrin for cancer-causing activity (carcinogenicity) was announced by HEW's National Cancer Institute in today's Federal Register.

Dieldrin-free photodieldrin, a breakdown product of the pesticides aldrin and dieldrin, was given to rats and mice for periods ranging from 59 to 80 weeks. According to a summary of the report included in the announcement, photodieldrin was not carcinogenic for rats or mice under the bioassay conditions.

The tests are part of the Institute's Carcinogenesis Bioassay Program. Copies of the report, Bioassay of Photodieldrin for Possible Carcinogenicity, are available from the Office of Cancer Communications, National Cancer Institute, Bethesda, Maryland 20014.

#

DHEW Publication No. (NIH) 77-817

. .